Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vázquez, Raúl M
OPAL, NCT03574779: A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer Oct 2019 - Dec 2019 : Proof-of-concept data from OPAL trial in combination with dostarlimab and Avastin for 2L+ PROC ovarian cancer	Recruiting	1b/2	125	Europe, Canada, US	Niraparib, ZEJULA, TSR-042, Bevacizumab, Avastin, Carboplatin, Paclitaxel	Tesaro, Inc.	Ovarian Neoplasms	08/24	03/26